Evidence from the clinical development of HF shows that an increase in titin-N2B increases cardiomyocyte stiffness, whereas an increase in titin-N2BA decreases cardiomyocyte stiffness, thereby increasing cardiomyocyte compliance. This evidence concerns the gene TTN and hydrops fetalis.